250 related articles for article (PubMed ID: 10411077)
1. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA
J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077
[No Abstract] [Full Text] [Related]
2. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of complexed prostatic specific antigen. A new challenge in PSA era].
Morote Robles J
Med Clin (Barc); 2004 Feb; 122(7):256-8. PubMed ID: 15012874
[No Abstract] [Full Text] [Related]
5. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
6. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
Pushkar' DIu; Rasner PI; Skobelev PP
Urologiia; 2001; (6):48-54. PubMed ID: 11785083
[No Abstract] [Full Text] [Related]
7. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
8. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.
Leidinger P; Keller A; Milchram L; Harz C; Hart M; Werth A; Lenhof HP; Weinhäusel A; Keck B; Wullich B; Ludwig N; Meese E
PLoS One; 2015; 10(6):e0128235. PubMed ID: 26039628
[TBL] [Abstract][Full Text] [Related]
9. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
11. Stage A prostate cancer today.
Kabalin JN
J Urol; 1993 Nov; 150(5 Pt 2):1749-50. PubMed ID: 7692113
[No Abstract] [Full Text] [Related]
12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
13. Prostatic specific antigen (PSA).
Alberti C
Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
[No Abstract] [Full Text] [Related]
14. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
Urologiia; 2001; (2):37-40. PubMed ID: 11490716
[TBL] [Abstract][Full Text] [Related]
15. Free PSA as a percentage of the total: where do we go from here?
Moore RA
Clin Chem; 1997 Sep; 43(9):1561-2. PubMed ID: 9299933
[No Abstract] [Full Text] [Related]
16. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Martin AA; Clejan S
J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
[No Abstract] [Full Text] [Related]
18. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.
Partin AW; Carter HB
Urol Clin North Am; 1996 Nov; 23(4):531-40. PubMed ID: 8948408
[TBL] [Abstract][Full Text] [Related]
19. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
20. Complexed prostate-specific antigen for the detection of prostate cancer.
Filella X; Truan D; Alcover J; Gutierrez R; Molina R; Coca F; Ballesta AM
Anticancer Res; 2004; 24(6):4181-5. PubMed ID: 15736470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
